Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30580338 | 0.85 | P2RY6 (0.51) | P2RY6P2RY14NT5EPOLBABL1 | |
| SCHEMBL3454561 | 0.84 | P2RY6 (0.52) | P2RY6P2RY14NT5EPOLBABL1 | |
| SCHEMBL21475717 | 0.83 | P2RY14 (0.39) | P2RY6P2RY14TYMPP2RY12P2RY2 | |
| SCHEMBL21475702 | 0.82 | TYMP (0.44) | NT5ETYMP | |
| SCHEMBL17231044 | 0.82 | P2RY6 (0.43) | P2RY6P2RY14NT5EPOLBABL1 | |
| SCHEMBL21475700 | 0.82 | PRMT6 (0.42) | TYMPGAPDHP2RY12 | |
| SCHEMBL7527348 | 0.80 | P2RY6 (0.53) | P2RY6P2RY14NT5EPOLBABL1 | |
| SCHEMBL26135104 | 0.80 | P2RY6 (0.52) | P2RY6P2RY14NT5EPOLBABL1 | |
| SCHEMBL21461829 | 0.79 | P2RY6 (0.41) | P2RY6P2RY14TYMPP2RY12P2RY2 | |
| SCHEMBL6928957 | 0.79 | P2RY6 (0.55) | P2RY6P2RY14NT5EPOLBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927140-B2 | Compositions and methods for reverse automated nucleic acid synthesis | THE UNIVERSITY OF TOLEDO (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190315794-A1 | Compositions and Methods for Reverse Automated Nucleic Acid Synthesis | THE UNIVERSITY OF TOLEDO (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315794-A1 | Compositions and Methods for Reverse Automated Nucleic Acid Synthesis | RNGTT, POLRMT, POLN | P2RY6 3816/4885P2RY14 3406/4885NT5E 65/4885 |
| US-10927140-B2 | Compositions and methods for reverse automated nucleic acid synthesis | RNGTT, POLRMT, POLN | P2RY6 3816/4885P2RY14 3406/4885NT5E 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.